Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Is it possible to reduce PCI costs without compromising safety?

Courtesy of Dr. Carlos Fava.

reduce PCI costs without compromising safetyHealth system costs have increased significantly and there have been attempts to reduce it without compromising the quality of PCI outcomes. The benefits of the transradial approach combined with same day discharge could help reach this goal.

 

This study included 279,987 MEDICARE PCI procedures where costs were analyzed. Cases were divided in 4 groups according to access site and discharge:

  • transradial approach and same day discharge, with 3,424 patients (1.2%)
  • transfemoral approach and same day discharge, 11,388 patients (4.1%)
  • transradial approach and next day discharge, 21,877 (7.8%),
  • transfemoral approach and next day discharge, 243,298 patients (86.9%), which was the overwhelming majority.

 

Transradial patients discharged the same day were younger, men, with lower cardiovascular risk and less comorbidities.

 

After variable adjusting, the transradial approach was associated to lower costs, which reached U$S 916 (CI 95%; U$S 778 to 1,035), as was same day discharge (U$S 3,502; CI 3486 to 3902). The total adjusted cost associated to the transradial approach with same day discharge was U$S 13,389 (CI 95%: 13,161 to 13.607), while the transfemoral approach with next day discharge cost U$S 17,076 (CI 95%: 16,999 to 17,147), with an absolute difference of U$S 3,689 (CI 95%: 3486 to 3905; p=<0.0001).

 

In-hospital evolution, bleeding, transfusion needs, vascular complications and hospitalization days were lower with the transradial approach.

 

Conclusion

Among patients who benefit from MEDICARE, the combination of the transradial approach with same day discharge was independently associated with less complications and lower in hospital costs. These findings have important implications in the current practice of PCI, since they improve costs and results.

 

Editorial Comment

This analysis shows it is possible to reduce costs and hospitalization days in selected patients.

 

As we know, the transradial approach has an important learning curve and we should also implement a hospital system to facilitate patient selection for same day discharge.

 

As interventionists, when it comes to cost reduction, it is essential to maintain the safety and quality of outcomes, and to remain cautious when deciding patient discharge.

 

Courtesy of Dr. Carlos Fava. Favaloro Foundation, Buenos Aires, Argentina.

 

Original Title: Cost Associated with Access Site and Same-Day discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention. An Evaluation of the Current Percutaneous Coronary Intervention care pathways in the United States.

Reference: Amit P Amin et al. JACC Cardiovasc Interv. 2017 Feb 27;10(4):342-351.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...